Treatment of patients with chronic hepatitis B with adefovir dipivoxil.

Abstract

Adefovir dipivoxil, a nucleotide analog of adenosine monophosphate, is an antiviral agent that suppresses hepatitis B virus (HBV) replication through inhibition of DNA polymerase and by chain termination. To determine the effectiveness of adefovir, three populations of patients with chronic hepatitis B patients were studied: hepatitis B e antigen (HBeAg)-positive patients, HBeAg-negative patients, and patients with lamivudine-resistant tyrosine-methionine-asparate-aspartate (YMDD) mutants. All three groups of patients were treated for 48 weeks with adefovir 10 mg/d, and significant reduction in serum HBV DNA and normalization of serum alanine aminotransferase (ALT) were noted. Significant improvement in liver histology was noted in HBeAg-positive and in HBeAg-negative patients. Significant HBeAg loss and HBeAg seroconversion rates were noted in HBeAg-positive patients and in lamivudine-resistant patients. No major drug-related side effects were noted. Adefovir 10 mg/d orally is safe and effective for treatment of chronic hepatitis B.

• Authors: Myron J Tong, Stanley S Tu
• Journal: Seminars in liver disease (Semin Liver Dis) Vol. 24 Suppl 1 Pg. 37-44 ( 2004) ISSN: 0272-8087 [Print] United States
• PMID: 15192800 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents
• DNA, Viral
• Hepatitis B e Antigens
• Organophosphonates
• Reverse Transcriptase Inhibitors
• Lamivudine
• Adenine
• adefovir dipivoxil

Topics

• Adenine (analogs & derivatives, therapeutic use)
• Antiviral Agents (therapeutic use)
• DNA, Viral (blood)
• Drug Resistance, Viral
• Hepatitis B e Antigens (blood)
• Hepatitis B virus (drug effects, genetics)
• Hepatitis B, Chronic (blood, drug therapy)
• Humans
• Lamivudine (pharmacology)
• Mutation
• Organophosphonates
• Reverse Transcriptase Inhibitors (therapeutic use)
• Treatment Outcome